Molecular markers and mortality in prostate cancer

Area of Science:

• Oncology
• Molecular Pathology
• Prognostic Biomarkers

Background:

• Prostate cancer prognosis relies on clinical factors like stage and grade.
• Identifying novel molecular markers can improve prognostic accuracy.
• Predicting long-term mortality is crucial for treatment decisions.

Purpose of the Study:

• To evaluate the independent prognostic effect of molecular factors in prostate cancer.
• To assess cell-cycle regulation markers and other molecular factors.
• To determine their role alongside traditional clinical factors in predicting mortality.

Main Methods:

• Retrospective analysis of 1274 incident prostate cancer cases from 64,545 US veterans (aged >/= 50).
• Data included demographics, clinical information, and immunohistochemical assays of molecular markers from biopsy tissue.
• Interim analysis of 250 patients with 8-13 years of follow-up for overall mortality.

Main Results:

• In 228 patients, median age was 72 years, median PSA 10.4 ng/mL.
• Bcl-2 staining (HR 2.14) and high microvessel density (HR 1.76) independently predicted mortality.
• These findings were significant after adjusting for traditional prognostic factors (P = 0.004 and P = 0.005, respectively).

Conclusions:

• Bcl-2 and microvessel density are independent predictors of death in prostate cancer.
• These molecular markers may aid in clinical decision-making for treatment.
• Further research can validate their role in prostate cancer prognosis.